This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
Eli Lilly said its daily obesity pill Foundayo eased obstructive sleep apnea in a late-stage trial. The company plans to seek U.S. approval for treating moderate-to-severe sleep apnea in adults with obesity by the end of the year, according to CNBC.
HOW THIS BRIEF WAS MADE 1 outlet: 1 national. Automated sourcing and summaries by the BLUF engine. Corrections
If approved for this use, the pill could add a treatment option for adults with obesity and sleep apnea. The article does not provide trial results or say the drug is approved for sleep apnea.
Lilly plans to file for U.S. approval by the end of the year. The article does not report a regulator decision or timing.
Lilly's planned U.S. filing
Trial details and any regulatory decision